Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: The prospective Malmö Diet and Cancer Study cardiovascular cohort

International Journal of Obesity

Volumn 37, Issue 4, 2013, Pages 598-603

  Enhorning S ^a,b   Bankir, L ^c   Bouby, N ^c   Struck, J ^d   Hedblad, B ^a,b   Persson, M ^a,b   Morgenthaler, N G ^d   Nilsson, P M ^a,b   Melander, O ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d THERMO FISHER SCIENTIFIC   (Germany)

Author keywords

abdominal obesity; arginine vasopressin; copeptin; diabetes; metabolic syndrome; microalbuminuria

Indexed keywords

ATRIAL NATRIURETIC FACTOR; C REACTIVE PROTEIN; COPEPTIN; CYSTATIN C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VASOPRESSIN;

ABDOMINAL OBESITY; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

AGE DISTRIBUTION; AGE OF ONSET; AGED; AGED, 80 AND OVER; ALBUMINURIA; ARGININE VASOPRESSIN; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; FEMALE; GLYCOPEPTIDES; HUMANS; LONGITUDINAL STUDIES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NEOPLASMS; OBESITY, ABDOMINAL; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; SEX DISTRIBUTION; SWEDEN; TIME FACTORS;

EID: 84876184092     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2012.88     Document Type: Article

References (37)

1. Whitton PD, Rodrigues LM, Hems DA. Stimulation by vasopressin, angiotensin and oxytocin of gluconeogenesis in hepatocyte suspensions. Biochem J 1978; 176: 893-898.
2. Keppens S, de Wulf H. The nature of the hepatic receptors involved in vaso-pressin-induced glycogenolysis. Biochim Biophys Acta 1979; 588: 63-69.
3. Abu-Basha EA, Yibchok-Anun S, Hsu WH. Glucose dependency of arginine vaso-pressin-induced insulin and glucagon release from the perfused rat pancreas. Metabolism 2002; 51: 1184-1190.
4. Holmes CL, Landry DW, Granton JT. Science review: Vasopressin and the cardiovascular system part 1-receptor physiology. Crit care 2003; 7: 427-434.
5. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin chem 2006; 52: 112-119.
6. Enhorning S, Wang TJ, Nilsson PM, Almgren P, Hedblad B, Berglund G et al. Plasma copeptin and the risk of diabetes mellitus. Circulation 2010; 121: 2102-2108.
7. Enhorning S, Struck J, Wirfalt E, Hedblad B, Morgenthaler NG, Melander O. Plasma Copeptin. A unifying factor behind the metabolic syndrome. J Clin Endocrinol Metab 2011; 96: E1065-E1072.
8. Mogensen CE. Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia 1999; 42: 263-285.
9. Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE). Am J Kidney Dis 1999; 33: 1004-1010.
10. Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003; 108: 1527-1532.
11. Bardoux P, Bichet DG, Martin H, Gallois Y, Marre M, Arthus MF et al. Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system. Nephrol Dial Transplant 2003; 18: 497-506.
12. Bouby N, Bachmann S, Bichet D, Bankir L. Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol 1990; 258: F973-F979.
13. Bardoux P, Bruneval P, Heudes D, Bouby N, Bankir L. Diabetes-induced albumi-nuria: role of antidiuretic hormone as revealed by chronic V2 receptor antagonism in rats. Nephrol Dial Transplant 2003; 18: 1755-1763.
14. Bardoux P, Martin H, Ahloulay M, Schmitt F, Bouby N, Trinh-Trang-Tan MM et al. Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: study in vasopressin-deficient Brattleboro rats. Proc Natl Acad Sci USA 1999; 96: 10397-10402.
15. Bouby N, Hassler C, Bankir L. Contribution of vasopressin to progression of chronic renal failure: study in Brattleboro rats. Life Sci 1999; 65: 991-1004.
16. Meijer E, Bakker SJ, de Jong PE, Homan van der Heide JJ, van Son WJ, Struck J et al. Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients. Transplantation 2009; 88: 561-567.
17. Meijer E, Bakker SJ, Halbesma N, de Jong PE, Struck J, Copeptin Gansevoort RT. A surrogate marker of vasopressin is associated with microalbuminuria in a large population cohort. Kidney Int 2010; 77: 29-36.
18. Fenske W, Wanner C, Allolio B, Drechsler C, Blouin K, Lilienthal J et al. Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus. J Am Soc Nephrol 2011; 22: 782-790.
19. Berglund G, Elmstahl S, Janzon L, Larsson SA. The Malmo Diet and Cancer Study. Design and feasibility. J Intern Med 1993; 233: 45-51.
20. Persson M, Hedblad B, Nelson JJ, Berglund G. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol 2007; 27: 1411-1416.
21. Fenske W, Stork S, Blechschmidt A, Maier SG, Morgenthaler NG, Allolio B. Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab 2009; 94: 123-129.
22. Morgenthaler NG, Struck J, Thomas B, Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin chem 2004; 50: 234-236.
23. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
24. Tencer J, Thysell H, Grubb A. Analysis of proteinuria: reference limits for urine excretion of albumin, protein HC, immunoglobulin G, kappa-and lambda-immunoreactivity, orosomucoid and alpha 1-antitrypsin. Scand J Clin Lab Invest 1996; 56: 691-700.
25. Kshirsagar AV, Bomback AS, Bang H, Gerber LM, Vupputuri S, Shoham DA et al. Association of C-reactive protein and microalbuminuria (from the National Health and Nutrition Examination Surveys, 1999 to 2004). Am J Cardiol 2008; 101: 401-406.
26. Magnusson M, Jujic A, Hedblad B, Engstrom G, Persson M, Struck J et al. Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malmo Diet and Cancer study. J Clin Endocrinol Metab 2012; 97: 638-645.
27. Rofe AM, Williamson DH. Mechanism for the 'anti-lipolytic' action of vasopressin in the starved rat. Biochem J 1983; 212: 899-902.
28. Aoyagi T, Birumachi J, Hiroyama M, Fujiwara Y, Sanbe A, Yamauchi J et al. Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice. Endocrinology 2007; 148: 2075-2084.
29. Hiroyama M, Aoyagi T, Fujiwara Y, Birumachi J, Shigematsu Y, Kiwaki K et al. Hypermetabolism of fat in V1a vasopressin receptor knockout mice. Mol Endocrinol 2007; 21: 247-258.
30. Fujiwara Y, Hiroyama M, Sanbe A, Yamauchi J, Tsujimoto G, Tanoue A. Mutual regulation of vasopressin-and oxytocin-induced glucagon secretion in V1b vasopressin receptor knockout mice. J Endocrinol 2007; 192: 361-369.
31. Masuki S, Mori M, Tabara Y, Miki T, Sakurai A, Morikawa M et al. Vasopressin V1a receptor polymorphism and interval walking training effects in middle-aged and older people. Hypertension 2010; 55: 747-754.
32. Enhorning S, Leosdottir M, Wallstrom P, Gullberg B, Berglund G, Wirfalt E et al. Relation between human vasopressin 1a gene variance, fat intake, and diabetes. Am J Clin Nutr 2009; 89: 400-406.
33. Tanoue A, Ito S, Honda K, Oshikawa S, Kitagawa Y, Koshimizu TA et al. The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. J Clin Invest 2004; 113: 302-309.
34. Rabadan-Diehl C, Aguilera G. Glucocorticoids increase vasopressin V1b receptor coupling to phospholipase C. Endocrinology 1998; 139: 3220-3226.
35. Mansia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. 2007 ESH-ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press 2007; 16: 135-232.
36. Jacobs Jr DR, Murtaugh MA, Steffes M, Yu X, Roseman J, Goetz FC. Gender-and race-specific determination of albumin excretion rate using albumin-to-creatinine ratio in single, untimed urine specimens: the Coronary Artery Risk Development in Young Adults Study. Am J Epidemiol 2002; 155: 1114-1119.
37. Perico N, Zoja C, Corna D, Rottoli D, Gaspari F, Haskell L et al. V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction. Kidney Int 2009; 76: 960-967.